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Type I collagen degradation product (ICTP) gives information about the
nature of bone metastases and has prognostic value in prostate cancer
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S_mmary Although osteosckerotic bone metastases are characteristic of prostate cancer, mixed metastases
with a lytic component are not uncommon. Type I collagen is synthesised by osteoblasts and accounts for
about 90% of the organic matrix of bone. We have used new specific immunoassays for PICP (carboxy-
terminal propeptide of type I procollagen) and ICTP (cross-linked carboxy-terminal telopeptide of type I
collagen) which allow simultaneous assessment of the synthesis and degradation of type I collagen respectively.
Forty patients with bone metastases due to prostate cancer at the time of diagnosis were investigated with
these methods. Twenty-three of them had sclerotic (S) and 17 had mixed metastases with sclerotic and lytic
components (S + L) as assessed by radiographs. The concentrations of PICP and ICTP in serum as well as the
activity of alkalin phosphatase (AP) were increased in all patients of the S + L group, who had more
aggressive bone disease and a shorter survival than the S group (P<0.017). The ICTP level was above the
reference range in half of the patients in the S group, whereas the PICP and AP levels were elevated in 35%.
Of the bone markers, only ICTP was of prognostic significance (P<0.05). We conclude that ICTP and PICP
give information about the type and activity of the skeletal metastases. In addition, ICTP predicts prog-
nosis.
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At the time of diagnosis of prostate cancer the tumour has
advanced beyond the prostatic capsule in 75% of the
patients, and distant metastases can be detected in nearly half
(Klein, 1979; Elder and Catalona, 1984). Bone metastases
occur in approximately 85% of patients who die of the
disease (McCrea et al., 1958; Jacobs et al., 1983). Although
bone-forming metast are charactenrstic of prostate cancer,
bone resorption is also accelerated, as evidenced by an inc-
rease in the urinary hydroxyproline excretion and by the
presence of lytic bone lesions in radiographs (Hopkins et al.,
1983; Urwin et al., 1985; Percival et al., 1987; Shimazaki et
al., 1990). Also, histomorphometnrc examination of skeletal
biopsies has confirmed an enhanced osteolysis (Charhon et
al., 1983; Urwin et al., 1985; Clarke et al., 1992; Taube et al.,
1994). The main symptom of bone metastases is pain, but
lytic lesions may sometimes also lead to pathological frac-
tures and hypercalcaemia. Although most patients with bony
metastases respond to the first-line hormonal therapy, the
median survival is between 2 and 3 years, and only 30% are
alive after 5 years (Murphy et al., 1983).
The major structural protein in bone is type I collagen,
which is synthesised by osteoblasts and accounts for about
90% of the organic matrix of bone (Risteli et al., 1993).
Thus, the metastatic process in bone tissue can in principle
be investigated by following the metabolism of type I col-
lagen. The synthesis of type I collagen can be followed
simultaneously by analysing the concentration of the car-
boxy-terminal propeptide of type I procollagen (PICP) (Mel-
kko et al., 1990). Bone resorption can be analysed by using a
novel radioimmunoassay which measures the serum concen-
tration of the carboxy-terminal pyridinoline cross-linked
telopeptide of type I collagen (ICTP) (Risteli et al., 1993).
ICTP is a peptide that is liberated during type I collagen
degradation and circulates in blood. The main aim of this
pilot study was to investigate how often bone resorption in
addition to bone formation is accelerated at the time of
diagnosis of bone metastases in prostate cancer and whether
it is of prognostic value.
Patuts
A total of 40 patients with skeletal metastases at the time of
diagnosis of prostate cancer were studied with respect to
collagen metabolism. The characteristics of the patients are
summarised in the Table I. The extent of metastases in bone
scintigram was established according to Soloway et al.
(1988). The types of metastases were evaluated by radio-
graphs, which showed sclerotic metastases without a visible
lytic component (S) in 23 patients (58%) and mixed metas-
tases with sclerotic and lytic components (S + L) in 17
patients (42%). Intermittent or constant bone pain had led to
Table I The characteristics of prostate cancer patients with bone
metastases detected at the time of diagnosis. Patients with mixed
sclerotic and lytic metastases (S+L) and with predominantly
sclerotic metastases (S) are presented separately
All S+L S
Number 40 17 23
Age (years)
Mean 68 69 68
Range 51-88 57-82 51-88
TNMa
T3 18 7 11
T4 22 10 12
Histological grade'
II 34 14 20
III 6 3 3
Bone scintigraphy
Soloway 1 (<6b) 9 0 9
Soloway 2 (<20b) 11 5 6
Soloway 3 (>20") 20 12 8
Soft-tissue metastases 18 10 8
Primary treatments
Orchiectomy 15 7 8
LHRH 15 6 9
Oestrogen 9 4 5
Anti-androgen I - 1
3TNM/grade cnrteria according to UICC (1987) (grade II,
moderately differentiated, grade III, poorly differentiated). "Number
of bone lesions.
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diagnostic examination in all patients. Soft-tissue metastases
were found in 18 patients (45%). Most of them were pelvic
or abdominal nodal masses. No patient had renal, hepatic or
pulmonary damage. The first treatment for metastatic disease
was surgical or chemical castration, oestrogen or anti-andro-
gens. When progression of skeletal metastases was evident,
estramustine phosphate was started in all patients (Estracyt
280 mg orally twice daily).
Methods
The activity of serum alkaline phosphatase (AP) and the
concentrations of prostate-specific antigen (PSA), PICP (Mel-
kko et al., 1990) and ICTP (Risteli et al., 1993) in serum
were measured before any therapy. Serum samples for the
determination of PICP and ICTP were stored at -20'C until
analysed. The whole skeleton was investigated by bone scinti-
graphy. X-ray examinations were made of the vertebral col-
umns, ribs, pelvis and proximal halves of the extremities.
Abdominal and pelvic ultrasound investigations were per-
formed to detect soft-tissue metastases.
Linear correlation coefficients were calculated between the
different markers. Before the analyses the values of the
markers were subjected to log transformation. t-tests were
used to compare the means of the various markers between
the groups with sclerotic and mixed sclerotic-lytic metas-
tases. The relationship of the markers to survival was
analysed by the Cox proportional hazards regression model
in a stepwise manner. Product-limit survival analysis was





ICTP was above the reference interval in 70% and PICP and
AP in 63% of patients. The percentages of the various
markers in the two groups with S or S + L metastases are
presented in Figure 1. Each of the values was above the
reference interval in the S + L group, whereas in the S group
the ICTP levels were increased in half of the patients and
35% ofthe patients had high PICP and AP values. The mean
concentrations of ICTP, PICP and AP were significantly
higher in the S + L group than in the S group (P<0.0001,
P<0.0001, P<0.001 respectively) (Table II). The fewer bone
metastases the patient had the lower were the concentrations
of various biochemical markers (Table II). The PSA concen-
trations were elevated in all patients (Table II).
Correlations and regressions between biochemical markers
In the whole group studied, a significant correlation was
observed only between the PICP and AP (r = 0.55, P =
0.001). Of all the markers ICTP was the most important
prognostic factor for survival (X2 = 2.93; P = 0.08), followed
by PSA, PICP and AP. Of the bone markers, ICTP was the
only one with prognostic signiflance (X: = 3.61; P = 0.05).
Survival
The median survival was 27 months for patients with S
metastases and 19 months for those with S + L metastases. A
significant difference in survival was seen between the groups
(Mantel-Cox P=0.017) (Figure 2).
We have investigated prostate cancer patients with skeletal
metastases at the time of diagnosis. The number of bone
metastases was evaluated by bone scan and the nature of the
sclerotic or lytic component by radiography. Skeletal metas-
tases can also be investigated with biochemical markers
(Francini et al., 1988; Mulders et al., 1989, 1992). Osteoblasts
synthesise type I collagen, which forms the main osteoid
matrix that undergoes mineralisation. In bone involved by
prostate cancer, excessive osteoid formation adjacent to
tumour tissue occurs, with increased numbers of active-
appearing osteoblasts (Jacobs, 1983). Also, bone resorption is
accelerated (Galasko, 1976; Clarke et al., 1992; Taube et al.,
1993). The increased osteoclast drive may be due to a physio-
logical adjustment of parathyroid hormone secretion in
response to the increased calcium demand in osteoblastic
Fge 1 Percentages of elevated ICTP, PICP and AP in the
patients with skeletal metastases due to prostate cancer. All
patients ( ), those with mixed sclerotic and lytic components
( [I1 ) and with predominantly sclerotic metastases ( M ) are
given separately.
Table II Behaviour of the biochemical markers (mean+s.d.)
according to the type ofskeletal metastases (S, sclerotic; S+L, mixed
sclerotic and lytic) and the extent of skeletal metastases (Soloway
classification)
ICTP PICP AP PSA
Mean+s.d. Mean+s.d. Mean+s.d. Mean+s.d.
Type
S 4.7 + 3.2 215 + 197 352 + 322 270 + 401
S+L 14.4+9.0*** 770 + 468*** 1238 + 1138** 537 + 810
Extent
Soloway 1 4.4 + 3.4 118 + 45 201 + 82 185 + 383
Soloway 2 9.8 + 10.5 469 + 427* 356 + 427' 187 + 348
Soloway 3 10.3 + 7.4* 651 + 434** 1108 + 1092* 544 + 737
*P<0.05, **P<0.001, ***P<0.0001, S vs S + L, Soloway I vs 2
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Fge 2 Cumulative proportion of surviving patients with scler-
otic type (continuous line) and mixed sclerotic and lytic type of
bone metastases (dotted line) caculated from the time of the
diagnosis of prostate cancer (Ml disease) (P<0.017 between the
groups, Mantel-Cox).
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metastases (Charhon et al., 1985; Urwin et al., 1985).
Another possibility is that the osteolysis may be due to
circulating tumour-generated factors such as epidermal
growth factor (EGF), transforming growth factor alpha
(TGF-a) and platelet-derived growth factor (PDGF), which
could promote osteoclast overactivity (Mundy, 1988; Vaes,
1988; Morris and Dodd, 1990).
The question of whether osteoblasts and osteoclasts are
activated in prostate cancer can be investigated by measurmg
the circulating concentrations of PICP and ICTP. Thus, the
elevation in serum concentrations of both PICP and ICTP
seen in the present study confirms the notion that not only
bone formation but also bone resorption is increased at the
time of diagnosis of skeletal metastases due to prostate
cancer.
ICITP was the most sensitive bone marker. It exceeded the
upper limit of the reference interval in 70% of patients and
was high in all patients of the S + L group. It was also
increased in half of patients without visible lytic features on
radiographs. ICTP in the present study seemed to be more
sensitive than urinary hydroxyproline (OHP) in the study of
Francini et al. (1988), which was elevated in only 50% of
patients with lytic components. Urinary OHP is dependent
on the diet; it is not specific for type I collagen degradation
and it is not easy for patients who have to collect urine for
24 h. The same applies to urinary pyridinoline derivates,
which are also non-specific with respect to collagen type and
relatively tedious to collect and measure (Elomaa et al.,
1992a). A high baseline ICTP concentration indicated poor
prognosis in the present study. It was the only one of the
biochemical markers with prognostic significance.
PICP and AP showed a good correlation. Surprisingly,
PICP was not more sensitive than AP, since the production
of type I procollagen is an early event, taking place already
during the time of proliferation of osteoblast precursor cells,
and a necessary prerequisite for the maturation of collagen,
in which phase AP is the most important gene product (Stein
et al., 1990). Possibly the synthesis of a large protein, such as
type I collagen, is disturbed or retarded by cancer cells or in
advanced cancer disease. On the other hand, in the study of
Francini et al. (1992), osteocalcin (OC), the third characteris-
tic product of osteoblasts, which is a protein obviously
involved in the mineralisation, seemed to be elevated more
often than AP in prevalently osteoblastic metastases (OC
84% vs AP 67%). In a study by Mulders et al. (1992) the
pretreatment value of AP was significantly related to sur-
vival. This is in contrast to our study, which showed no
significant prognostic value for PICP or AP. In the same
study PSA was the best indicator of treatment response but
had no prognostic value. This is in accordance with our
study, in which ICTP surpassed PSA as prognostic indicator.
According to Killian et al. (1988), ofall biochemical markers
for prostate cancer, including PSA, total acid phosphatase,
prostate-specific acid phosphatase and AP, PSA most accur-
ately reflects the tumour status of the patient and provides
the greatest prognostic information in advanced prostate
cancer. It must, however, be noted that PSA levels reflect
both soft-tissue and bone metastases. When our patients were
grouped according to the type of bone metastases, those with
a lytic component had higher ICTP, PICP and AP levels,
indicating more accelerated bone turnover; they showed more
aggressive disease, more elevated PSA levels, a higher percen-
tage of histological grade IIH disease (S + L 21% vs S 15%)
and more bone and nodal metastases than patients with
purely sclerotic metastases. They were observed to succumb
faster than patients with purely sclerotic metastases. Probably
these more aggressive cancers produce more bone-resorbing
mediators and cause other connective tissue destruction, and
this also influences the prognosis. Patients with both nodal
and bone metastases seem to have a worse prognosis than
those with only nodal disease (Sandhu, 1990). This may
explain why the group with osteolysis also had a shorter
survival. On the other hand, we have previously shown that
initial ICIP is a significant predictor for survival in multiple
myeloma (Elomaa et al., 1992a).
The evaluation of lytic and sclerotic bone metastases in
radiographs is problematic. We have defined sclerotic metas-
tases as those without any visible lytic component and mixed
lytic and sclerotic metastases as those with visible lytic com-
ponent by the side of sclerotic features, Francini et al. (1988)
described skeletal metastase on radiographs as prevalently
osteoblastic and prevalently osteolytic components. Thus, it
is not surprising that the levels of the various markers are
not similarly distributed.
We conclude that type I collagen metabolites in serum are
often increased at the time of skeletal metastases due to
prostate cancer. The determination of PICP and ICTP con-
centrations gives information about the type and activity of
bone metastases. This may help in selecting the modality of
therapy. ICTP is a sensitive and specific bone resorption
marker. It also gives information about the prognosis. Fur-
ther studies should be aimed at evaluating the usefulness of
these markers in both the localised and advanced phases of
the disease. It will be interesting to see how often sclerotic
metastases will transform to lytic ones in the course of
disease and whether an increase in the ETP concentration can
precede radiologically visible osteolytic changes. Such
patients could benefit from bisphosphonate treatment
(Adami et al., 1985, 1989; Clarke et al., 1989; Lipton et al.,
1989; Elomaa et al., 1992b). It is also worth investigating
whether ICTP can help in the evaluation of the treatment
response as it does in multiple myeloma (Elomaa et al.,
1992a). Moreover, it would be interesting to know whether
circulating PICP concentrations are elevated before visible
bone metastases, and whether PICP can detect bone metas-
tases earlier than does AP or bone scans. These assays could
perhaps replace the routine bone scan in follow-up, as does
the PSA assay, which seems to be ofmore importance for the
detection and monitoring of prostatic cancer than as a
pretreatment prognostic factor (Mulders et al., 1992).
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